Zacks Research Has Negative Outlook of IRWD FY2027 Earnings

Key Points

• Zacks Research has revised its FY2027 EPS estimate for Ironwood Pharmaceuticals to (-$0.03), a decrease from a previous estimate of (-$0.02), while the consensus for current full-year earnings is $0.10 per share.
• Ironwood's stock rating has seen mixed reviews, with Wall Street Zen upgrading it to a "buy" and Craig Hallum downgrading it to a "hold."
• Despite recent downgrades, Ironwood Pharmaceuticals reported a quarterly EPS of $0.14, surpassing estimates and achieving revenues of $85.24 million against an expected $62.02 million.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Investment analysts at Zacks Research reduced their FY2027 earnings per share (EPS) estimates for shares of Ironwood Pharmaceuticals in a report released on Tuesday, August 5th. Zacks Research analyst R. Department now forecasts that the biotechnology company will earn ($0.03) per share for the year, down from their previous forecast of ($0.02). The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share.

A number of other equities analysts also recently issued reports on the company. Craig Hallum downgraded Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th. Citizens Jmp cut Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Monday, April 14th. Wells Fargo & Company reiterated an "equal weight" rating and set a $1.00 target price (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Jefferies Financial Group restated a "hold" rating and set a $0.70 price objective (down previously from $8.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Finally, Leerink Partners cut their target price on Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating on the stock in a research report on Monday, April 14th. Six analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Ironwood Pharmaceuticals presently has a consensus rating of "Hold" and a consensus target price of $4.94.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD stock traded up $0.15 during trading hours on Friday, reaching $0.98. 1,342,746 shares of the company's stock were exchanged, compared to its average volume of 2,912,281. The company has a market cap of $158.99 million, a P/E ratio of -19.65 and a beta of 0.33. The company's 50 day moving average is $0.75 and its two-hundred day moving average is $1.13. Ironwood Pharmaceuticals has a 1 year low of $0.53 and a 1 year high of $5.21.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.16. The business had revenue of $85.24 million during the quarter, compared to the consensus estimate of $62.02 million. Ironwood Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 2.25%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. purchased a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth about $68,000. KLP Kapitalforvaltning AS bought a new stake in Ironwood Pharmaceuticals in the fourth quarter valued at about $107,000. Norges Bank bought a new stake in Ironwood Pharmaceuticals in the fourth quarter valued at about $1,118,000. Geode Capital Management LLC increased its holdings in Ironwood Pharmaceuticals by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 3,306,570 shares of the biotechnology company's stock valued at $14,652,000 after buying an additional 13,028 shares during the last quarter. Finally, Envestnet Asset Management Inc. bought a new stake in Ironwood Pharmaceuticals in the fourth quarter valued at about $50,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.